6a0e4bf77c2f4f6618ed4036165eb3a517dc9da2-00001186-2

Tweets

Follow us @PLRI

Court-based research: collaborating with the justice system to enhance STI services for vulnerable women in the US http://t.co/3vEaFQVO
The fractal queerness of non-heteronormative migrant #sexworkers in the UK by Nick Mae http://t.co/X7oGFeDI
‘only 31% of the sample of indirect sex workers reported having been engaged in commercial sex in the last 12 months’
Old but good. Violence and Exposure to HIV among #sexworkers in Phnom Penh http://t.co/rkrRGiBa
Someone is Wrong on the Internet: #sex workers’ access to accurate information 

Anal sex, vaginal practices and HIV incidence in female sex workers in urban Kenya: Implications for development of intravaginal HIV prevention methods

Multiple intravaginal HIV prevention methods, including microbicide gels, barriers and intravaginal rings, are in clinical development in Africa.

Development of intravaginal HIV prevention products requires an understanding of sexual behavior, sexually transmitted infection (STI) and vaginitis prevalences, and sexual and vaginal practices in potential target populations. We assessed these factors in a cohort of Kenyan female sex workers (FSW). Methods: Women who reported exchanging sex for money/gifts at least 3 times in the past month and were HIV uninfected were enrolled and followed for 6 months. STI prevalence and HIV incidence were analyzed by multivariate logistic regression analysis, controlling for demographic and behavioral factors. Results: Thirty seven percent (74/200) reported having had anal sex. Frequency of anal sex was higher with regular and casual partners than with primary partners. Women were less likely to use condoms for anal sex than for vaginal sex with regular or casual partners. Vaginal washing was universal (100%). HIV incidence was 5.6 per 100 person-years (95% CI 1.62, 11.67). HIV incidence was not associated with any demographic or risk behavior. Conclusions: The relatively high rate of anal sex and universal vaginal washing may complicate both safety and efficacy evaluation of intravaginal products and should be taken into account in trial design. This FSW population had significant HIV incidence and needs continued HIV prevention interventions.

Author: 

Frances H Priddy, Sabina Wakasiaka and others